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Arthritis is a debilitating condition that affects ~50 million 
adults in the USA, a prevalence that is projected to rise by 
~60% in the next two decades1. Osteoarthritis (OA), the 
most common type of arthritis2, is associated with pain 
and loss of joint function. Although the aetiology of OA 
can be idiopathic, the disease is often characterized by 
cartilage degeneration in articulating joints as a result of 
‘wear and tear’ or injury, including sports-related injuries. 
For example, in one study, individuals who sustained knee 
injuries were 7.4 times more likely to develop OA than 
those who had not sustained knee injuries3. Meniscus and 
anterior cruciate ligament (ACL) tears can also contribute 
to the development of OA because damage to these struc-
tures alters joint loading4,5; OA occurs 10–20 years after 
injury in ~50% of patients who sustain meniscal or ACL 
tears5. Globally, knee and hip cartilage degeneration is 
one of the leading contributors to disability6. Rheumatoid 
arthritis (RA), the second most common type of arthri-
tis, is a chronic autoimmune disease characterized by 
inflammation and deterioration of joints that results in 
loss of function, and affects 1.3 million adults in the USA7. 
Worldwide, arthritides such as OA and RA represent a 
substantial burden to health-care systems8,9.
Despite the pervasiveness of OA, most current treat-
ments are palliative and do not prevent further joint 
degeneration10. Likewise, treatments for RA often reduce 
joint inflammation without treating cartilage damage11. 
Ultimately, many patients with arthritis will require total 
joint arthroplasty, an invasive end-stage treatment that 
uses implants that wear out over time. Current surgical 
strategies for cartilage repair are designed to treat small 
defects in cartilage and are not directly indicated for 
use in inflamed joints, such as those that occur in RA. 
However, using tissue engineering strategies, which focus 
on the complete regeneration of articular cartilage12,13 and 
menisci14,15, researchers can potentially create neotissue 
that has been modified to withstand immune-mediated 
degeneration. Thus, in the future, tissue engineering 
strategies could offer new therapeutic avenues for patients 
with RA before total joint arthroplasty is indicated.
In this Review, we begin by discussing current sur-
gical techniques, including tissue-engineered treat-
ments, defined here as cell-based (scaffold-free and 
scaffold-based) therapies, for the repair of articular carti-
lage and meniscus lesions. We then discuss advances in 
tissue engineering research for articular cartilage and 
meniscus regeneration, including novel scaffold-based 
and scaffold-free approaches, promising sources of cells 
for cell-based therapies and emerging data on biochem-
ical and biomechanical stimuli. We also present data 
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on cell-based tissue-engineered products for cartilage 
regeneration currently in development. Finally, we dis-
cuss scientific and regulatory obstacles to the clinical 
translation of tissue-engineered technologies, as well as 
future directions to encourage researchers in the field to 
overcome these challenges.
Current surgical strategies
Repairing articular cartilage defects
Articular cartilage is predominantly composed of type II 
collagen and glycosaminoglycans and is avascular 
with low cellularity (Fig. 1a) and, therefore, has a low 
healing capacity. Clinicians encounter articular carti-
lage damage in more than half of knee arthroscopies 
performed as a result of injury or symptoms of carti-
lage damage16,17. Specifically, chondral lesions (defects 
that do not penetrate into the subchondral bone) and 
osteochondral lesions (defects that penetrate into the 
subchondral bone) were found in 61% of patients sur-
veyed12,17. Because cartilage defects are often asymp-
tomatic18, careful assessment is required to determine 
whether the lesion is the source of pain in an individual. 
Current surgical strategies aim to repair small (<4 cm2) 
defects in cartilage to prevent further degeneration 
and progression towards OA (Fig. 1b). Cartilage repair 
strategies for the knee are well-established and produce 
improvements in clinical outcomes for patients19,20. 
However, repair of hip cartilage is less frequently per-
formed than repair of knee cartilage. The use of bone 
marrow stimulation, grafting and cell-based techni-
ques for articular cartilage repair are discussed in the 
following section.
Bone marrow stimulation and augmentation. Bone 
marrow stimulation techniques for small (<4 cm2), 
contained, defects have evolved from open debridement 
of damaged cartilage and removal of subchondral bone 
to the Steadman microfracture technique21, in which 
the calcified cartilage is removed and an awl is used to 
create perforations in the subchondral plate. Bone mar-
row released into the defect forms a blood clot, which 
might ultimately lead to the formation of fibrocarti-
lage. Unlike hyaline cartilage, fibrocartilage is rich in 
type I collagen and is of limited durability. Individuals 
treated with microfracture show initial clinical improve-
ment after surgery, but have an accelerated decline in 
clinical outcome scores and a higher failure rate during 
long-term follow-up than those treated with osteochon-
dral autograft treatment22,23. To overcome the short-
comings of microfracture, augmented bone marrow 
stimulation techniques were subsequently developed, 
including the concomitant injection of molecules such 
as growth factors, the use of acellular scaffolds (such as 
collagen membranes) or liquid hydrogels, and the use 
of micronized acellular cartilage extracellular matrix 
from allografts24. However, more high-quality studies 
are needed to demonstrate the superiority of augmented 
bone marrow stimulation techniques over other estab-
lished procedures, such as microfracture or autologous 
chondrocyte implantation (ACI)25.
Autografts and allografts. Osteochondral autograft 
transfer delivers viable, mature hyaline cartilage–bone 
units into chondral defects. These osteochondral grafts 
can bear load in the early postoperative period, enab-
ling faster rehabilitation than following other, cur-
rently available, cell-based cartilage repair strategies26. 
Osteochondral autograft transfer involves the harvest-
ing of ‘plugs’ from regions of the distal femur that bear 
low loads (such as the intercondylar notch or medial 
or lateral trochlea) and, therefore, its use is reserved 
for small chondral defects (<2 cm2) owing to limited 
graft availability27.
The avascular nature of cartilage renders it immune 
privileged28, thereby opening up the potential for alloge-
neic approaches. Osteochondral allograft transplantation 
does not have the donor site limitations of osteochondral 
autograft transfer and can be used in revision surgery for 
failed cartilage repairs, making osteochondral allograft-
ing an appealing technique, although the availability of 
allograft tissue limits its use. Matching allografts to the 
shape and contours of the native knee architecture can 
also be difficult to achieve, potentially creating bio-
mechanical loading imbalances and resulting in degen-
erative joint changes29,30. Techniques to improve the 
viability of chondrocytes in fresh osteochondral allo-
grafts and to accelerate the remodelling of graft tissue 
into host tissue are continually being investigated 
because both factors seem to be important for the 
longevity of the transplanted allograft31,32.
Both osteochondral autograft transfer and osteo-
chondral allograft transplantation have produced high 
rates of long-term graft survival, as well as high degrees 
of reported patient satisfaction and return-to-play 
among athletes26,33–35. For example, a 2016 systematic 
review found that ~90% of patients who underwent 
osteochondral autograft transfer had good or excellent 
outcomes at up to 10 years after surgery19. Another 
study showed that the survival of fresh osteochondral 
allografts was 82% at 10 years and 66% at 20 years 
after transplantation33. Cryopreserved osteochondral 
allografts (Cartiform), fresh osteochondral allografts 
(ProChondrix) and particulated juvenile allograft carti-
lage (DeNovo NT), which are processed by laser cutting 
or mincing, have also been used to treat articular carti-
lage defects36; however, short-term and long-term data 
are needed to determine the clinical success of these 
products.
Key points
•	Current	cartilage	repair	techniques	include	surgery	and	cell-based	therapies	for	
articular	cartilage,	and	surgery	for	meniscus	repair;	however,	such	treatments	have	
limited	capacity	to	induce	regeneration.
•	Tissue	engineering	strategies	to	create	cartilage	using	a	variety	of	cell	sources	and	
exogenous	stimuli	have	made	advances	towards	replicating	the	native	architecture	
and	functional	properties	of	cartilage.
•	Most	cell-based	tissue	engineering	products	currently	in	clinical	trials	are	indicated	
for	knee	articular	cartilage,	with	very	few	indicated	for	hip	cartilage	or	the	meniscus.
•	Allogeneic	and	non-articulating	cartilage	might	serve	as	additional	cell	sources	for	
engineered	articular	cartilage	and	meniscus	products.
•	The	pro-inflammatory	environment	of	arthritic	joints	and	issues	surrounding	
neotissue	integration	need	to	be	addressed	to	maximize	the	clinical	translation		
of	new	tissue-engineered	products.
Debridement
The removal of damaged tissue 
and/or torn fragments from a 
defect.
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Cell-based techniques. Current cell-based cartilage 
repair techniques enable the implant to be contoured to 
the recipient defect, making these techniques attractive 
for treating large (>3–4 cm2) chondral lesions in areas 
with variable topographies, such as the patellofemo-
ral joint or acetabulum. ACI requires two operations: 
chondrocytes are harvested from healthy articular carti-
lage in one operation and are then re-implanted into the 
chondral defect in a second operation after expansion 
in culture. A newer iteration of this technique, known 
as matrix-induced ACI (MACI), includes seeding of 
the chondrocytes onto a scaffold before implantation37. 
Patients treated with MACI have reported substantial 
long-term improvements in knee function and high 
rates of satisfaction38,39. In one study, at 5 years after sur-
gery, 93% of patients expressed satisfaction with their 
postoperative pain relief, 90% had an improved ability to 
perform daily activities and 80% were able to participate 
more in sports compared with before the operation38. 
However, procedures that require only one ope ration 
are currently more appealing for clinicians than ACI 
or MACI.
ProChondrix
DeNovo NT
a  Articular cartilage structure and types of defect
b  Repair strategies
Chondrocytes
Type II collagen
Glycosamino-
glycans  
Tide mark
Subchondral
bone
Chondral
Microfracture Osteochondral autograft transfer Osteochondral allograft transplantation
Osteochondral
Matrix-induced autologous chondrocyte implantation
Cell isolation and
expansion in vitro
Processed allograft cartilage implantation
Cartiform
Fig. 1 | articular cartilage structure and treatment methods. a | Articular cartilage consists of chondrocytes embedded 
in a defined structure of collagen fibres and glycosaminoglycans. Two main types of defect can occur: chondral defects, 
which only penetrate the cartilage, and osteochondral defects, which also penetrate the subchondral bone. b | Currently 
used repair strategies for cartilage defects include microfracture, osteochondral autograft transfer, osteochondral 
allograft transplantation, implantation of processed allograft cartilage such as DeNovo NT, ProChondrix and Cartiform, 
and matrix-induced autologous chondrocyte implantation. The choice of treatment method depends on the size and type 
of the defect, the expertise and preferences of the surgeon and patient-specific factors such as age and activity level.
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Repairing meniscus defects
Two semicircular, wedge-shaped menisci are located 
between the distal femur and the tibial plateau and serve 
to distribute loads and protect articular cartilage. Each 
meniscus has two distinct regions (Fig. 2a): the outer, 
vascular, neural region (the red–red zone), which con-
tains elongated fibroblast-like cells and predo minantly 
type I collagen, and the inner, avascular, aneural zone 
(the white–white zone), which contains rounded 
chondrocyte-like cells (fibrochondrocytes) and predom-
inantly type II collagen. These two zones are separated 
by the red–white zone, which has characteristics of both 
the red–red zone and the white–white zone. The menis-
cus functions by distributing load through its circumfer-
entially aligned collagen fibres (Fig. 2a). Meniscus tears 
disrupt this function; however, only a small proportion 
of tears are considered repairable on the basis of tissue 
vascularity, tear pattern, anatomical location and tear 
acuity (Fig. 2b). For example, vertical longitudinal tears 
within the red–red or red–white zone of the meniscus 
are often amenable to repair40. Horizontal and radial 
tears are thought to rarely heal owing to incursion into 
the avascular white–white zone. Furthermore, radial 
tears disrupt the circumferential collagen fibres that are 
critical for maintaining hoop stresses, whereas circum-
ferential vertical or horizontal tears can leave the menis-
cus with the potential for residual functionality because 
these tears follow the circumferential collagen fibres. The 
length, depth and size of tear, as well as joint stability and 
other patient-related factors such as age and symptoms 
also affect healing41,42. Despite our understanding of the 
crucial function of the meniscus in knee biomechanics, 
partial meniscectomy to remove unstable, damaged por-
tions of the tear remains the gold standard for surgical 
treatment of meniscus tears, and accounts for half of the 
knee arthroscopic procedures performed in the USA43. 
However, both partial and total meniscectomy are linked 
to the development of knee OA44, a fact that provides 
motivation for the development of novel interventions 
such as cell-based regenerative therapies.
Reduction of meniscal tears. Lesions in the meniscus 
that are mechanically unstable, complex or of a degen-
erative nature are conventionally treated with partial 
meniscectomy; however, attempts to reduce meniscal 
tears instead of performing partial meniscectomy have 
become more common during the past 15 years45 (Fig. 2c). 
Meniscus defect reduction (often described by clinicians 
as meniscus repair) is usually accomplished by closure 
of the tear with sutures and/or anchors. For example, 
suturing of defects in the red–red and red–white zones 
led to satisfactory clinical healing in 76% of patients with 
meniscal tears46. Tear reduction also resulted in meniscus 
preservation without degeneration in younger patients 
(aged between 16 and 52 years)47,48. Meniscal tear reduc-
tions performed concurrently with ACL reconstruction 
have superior healing rates than meniscal tear reduc-
tions alone49, potentially owing to the intra-articular 
release of cells and growth factors from the bone mar-
row that occurs when drilling a bone tunnel during 
ACL reconstruction50. Parameters affecting menis-
cus repair are probably multifactorial, but biological 
augmentation techniques, such as mechanical stimula-
tion of the adjacent synovium or meniscus by rasping or 
radial trephination51,52, the addition of an exogenous fibrin 
clot53 or the introduction of bone marrow stem cells by 
marrow venting54, are thought to promote healing.
Allografts. Meniscus allograft transplantation is the only 
option for total meniscus replacement, and is widely per-
formed following total or near total meniscectomy (Fig. 2d). 
Allograft transplantation is indicated in patients who have a 
stable, correctly aligned joint and, at most, early knee OA55. 
Meniscus allografts can be inserted with several forms of 
attached bone, such as bone plugs, a common bone bridge 
or a hemi-plateau, or without attached bone56. In particular, 
meniscus fixation using bone plugs leads to better load 
transmission than fixation without using bone plugs56. 
Appropriate allograft sizing to the recipient knee56 is 
also an important factor for tissue healing57 and for the 
preservation of knee biomechanics58. Allograft recipients 
have good rates of clinical improvement. In a long-term 
follow-up study (mean 152 months) in 30 patients who 
received meniscal allografts, all patients had improved 
function (as measured by Lysholm score, short form-36 
(SF-36) score and Knee Injury and Osteoarthritis Outcome 
Score (KOOS)), and 90% were satisfied with the outcome 
of the surgery59. However, meniscus replacement does not 
prevent joint space narrowing60.
Synthetic implants. Partial meniscus replacements, 
such as collagen meniscus implants (CMI, available 
in the USA) and polyurethane polymeric implants 
(Actifit, available in Europe), can be used in patients 
with segmental meniscus defects, an intact peripheral 
rim and limited articular cartilage damage61. CMI pro-
vided substantial pain relief and functional improve-
ment and had a low rate of implant failure at follow-up 
(mean 9.6 years) in patients receiving implants following 
partial meniscectomy62. Similarly, polyurethane poly-
meric implants improved clinical outcomes in patients 
following partial meniscectomy up to 4 years after 
implantation63. For replacement of the entire meniscus, 
a polyethylene-reinforced polycarbonate urethane pros-
thetic (NuSurface) is currently in FDA clinical trials64. 
Although synthetic meniscus implants can improve 
clinical outcomes, their use is limited by several short-
comings and technical difficulties: synthetic implants do 
not result in meniscus regeneration; the ability of syn-
thetic implants to stop progression of OA is unproven; 
synthetic implants are difficult to place properly within 
the defect using an arthroscopic approach; and syn-
thetic implants are challenging to handle and suture65. 
Therefore, a great need exists for cell-based approaches 
that can regenerate damaged meniscus.
Age-related differences in outcomes
Parameters that affect the outcomes of articular cartilage 
and meniscus repair are multifactorial, but gene rally, 
increased patient age has a negative correlation with 
good outcomes, in particular after bone marrow stimu-
lation techniques. Treatments that are acceptable for 
use in paediatric and adolescent patients might not be 
suitable for use in adults, who tend to have degenerative, 
Hoop stresses
Compressive forces 
experienced by the meniscus 
in the circumferential direction.
Rasping
Mechanical scraping to expose 
fresh and/or bleeding tissue.
Radial trephination
Puncturing small holes into the 
joint lining and/or synovium 
and into the tissue to stimulate 
healing.
Bone plugs
Created or fashioned bone 
cylinders containing the 
enthesis of the meniscal roots.
Common bone bridge
Excised bone containing and 
preserving the anatomic 
relationship between the 
anterior and posterior meniscal 
horns (also known as ‘slot’).
Hemi-plateau
Half of the tibial plateau, 
containing the articular surface, 
subchondral bone and 
meniscus with root 
attachments.
Lysholm score
A scoring system used to 
measure changes in limping, 
support, locking, instability, 
pain, swelling, stair climbing 
and squatting (originally 
developed to evaluate 
outcomes of knee ligament 
surgery).
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a  Meniscus structure
Chondrocyte-like cells
Blood vessels
Fibroblast-like cells
Cross-section
b  Types of defect
c  Reduction strategies
Vertical tears
Longitudinal (bucket handle) Radial (transverse) Oblique (parrot beak) Flap Cleavage
Horizontal tears
Top view
Circumferential
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Radial
ﬁbres
R–R
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R–W
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W–W
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Defect closure Partial meniscectomy
d  Replacement strategies
Synthetic replacement
Fig. 2 | meniscus structure and treatment methods. a | The meniscus consists of three main zones: red–red (R–R),  
red–white (R–W) and white–white (W–W). The R–R zone is fully vascularized and the W–W zone is avascular. b | A variety  
of different types of defect can occur in the meniscus, some of which are easier to repair than others owing to their 
intrusion into vascular or avascular zones. c | Reduction strategies in current use include defect closure with sutures or 
anchors and the trimming of torn pieces (partial or total meniscectomy). d | Replacement strategies in current use include 
allograft transplantation and the use of synthetic implants. As with articular cartilage, the size and type of defect, the 
expertise and preferences of the surgeon and patient-specific factors such as age and activity level affect the choice of 
treatment method.
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rather than acute traumatic, lesions. Two main princi-
ples exist for treating paediatric articular cartilage or 
meniscus defects: techniques must be effective to help 
prevent the risk of developing OA at a young age; and 
joint anatomy and functionality must be restored to 
ensure symptomatic relief and resumption of pre-injury 
levels of physical activity66. Given the increase in paedi-
atric joint injuries67,68, potentially as a result of increased 
participation in sports, the development of therapies that 
will withstand the test of time is greatly needed.
Treatment of articular cartilage defects in young 
patients. Although many of the same techniques are 
used to treat cartilage lesions in children and adolescents 
as in adults, outcomes can differ. For microfracture, 
patients older than 40 years had worse outcomes than 
younger patients (<30 years of age) in many studies69–72, 
potentially because older patients have fewer bone mar-
row progenitor cells and diminished regenerative capa-
city compared with younger patients. A similar trend 
occurs with osteochondral autograft transfer, for which 
better outcomes have been reported in young patients 
(<30 years of age)73. By contrast, 88% of paediatric and 
adolescent patients had successful outcomes following 
osteochondral allograft transplantation after a median 
of 2.7 years74, similar to success rates reported in adults75. 
ACI in young patients (≤18 years of age) produced an 
improvement in postoperative outcomes in 84–96% of 
patients at 2–4 years of follow-up76,77, which was higher 
than the rate of improvement in adults for the same 
follow-up period (78–83%)78,79. Overall, in younger 
patients (≤40 years of age), many of whom are athletes, 
osteochondral autograft transfer22,80 and ACI or MACI81 
might result in better long-term outcomes and higher 
rates of return-to-play than microfracture.
Treatment of meniscus defects in young patients. As 
with articular cartilage, outcomes associated with treat-
ing meniscus pathologies differ as a result of multiple 
factors, including age and tear type. In general, meniscus 
allograft transplantation is indicated in young patients 
(<50 years of age) with meniscal deficiency, and is 
contraindicated in patients with evidence of advanced 
OA82. In patients aged 16 years or younger, an improved 
Lysholm score and a revision rate of 22% have been 
reported after a mean follow-up of 7.2 years following 
meniscus allograft transplantation83. For meniscal tear 
reduction, most studies in a meta-analysis showed lit-
tle difference in failure rates between patients under 
and over the age of 40 years84,85. Another meta-analysis 
on meniscus repair that included 13 studies in adults 
showed a healing rate of 62–79% and a pooled re-tear 
rate of 23% after >5 years86. Comparisons between sur-
gical outcomes in paediatric and adolescent patients 
versus adult patients need to take into consideration the 
types of tear that are being reduced. In paediatric and 
adolescent patients, meniscus defect reduction can be 
attempted for most meniscal tears regardless of zone, 
size and patient-specific factors, as the priority is to pre-
serve the knee. By contrast, in adults, meniscus defect 
reduction is usually only performed for tears that have 
a high potential to heal, such as peripheral tears. Thus, 
despite the beneficial healing environment in paediatric 
and adolescent patients that results from a high degree 
of vascularization and increased cellular metabolism87,88, 
healing rates in paediatric and adolescent patients com-
pared with adult patients can seem similar because of the 
types of tears that are treated.
Tissue engineering strategies
Current surgical approaches do not provide long-term 
solutions for articular cartilage and meniscus regener-
ation, but tissue engineering techniques could provide 
alternative treatment strategies. Scaffolds, cells and 
biochemical and biomechanical stimuli, the main tools 
used to create engineered tissues (Fig. 3), are discussed in 
this section, as well as advances in cartilage engineering 
and the results of preclinical and clinical studies using 
engineered articular cartilage and meniscus products.
Scaffold and scaffold-free approaches
A variety of synthetic or natural materials, including 
polylactides, polyglycolides and silk, have been investi-
gated for use as scaffolds for engineered articular carti-
lage89 and meniscus88. Decellularized cartilage-derived 
matrix has also been investigated for use as a scaffold in 
cartilage regeneration90,91. For example, decellularized 
cartilage-derived matrix scaffolds inhibit the hypertrophic 
differentiation of embedded mesenchymal stem cells 
(MSCs) and promote the synthesis of cartilage matrix by 
these cells90. Decellularized extracellular matrix scaffolds 
derived from inner and outer regions of the meniscus sup-
port the differentiation of MSCs towards fibrochondro-
cyte and elongated fibroblastic phenotypes, respectively91. 
Various other types of scaffolds, including hydrogels and 
porous polymeric structures, are also under investigation 
for use in articular cartilage and meniscus tissue engineer-
ing. For example, injectable hydrogels, which can form 
irregular shapes to better fill defects, enable the use of 
minimally invasive implantation methods92. In the past 
20 years, both natural materials (for example, alginate and 
hyaluronan) and synthetic materials (for example, poly-
caprolactone and polylactic acid) have been used in 3D 
printers to create anatomically shaped scaffolds for artic-
ular cartilage and menisci93,94. The advantages of using 
scaffolds for cartilage engineering include the ability to 
incorporate growth factors into the scaffold and the initial 
mechanical stability that they provide95.
Despite the advantages of scaffolds, scaffold use 
can also result in degradation-associated toxicity, 
stress shielding, altered cell phenotypes and hindrances to 
remodelling95. These difficulties have provided the moti-
vation for investigations into scaffold-free techniques 
to engineer cartilage96 and menisci97. In particular, the 
scaffold-free self-assembling process facilitates cell-to-cell 
interactions by minimizing free energy, and recapitulates 
the conditions of cartilage development, which result in 
changes in the ratios of chondroitin 6-sulfate to chon-
droitin 4-sulfate and type VI collagen to type II colla-
gen within the engineered neocartilage as it develops98. 
Through the use of biochemical and biomechani-
cal stimuli, cartilage engineered using a scaffold-free 
approach has attained functional properties on a par 
with native tissue99. For example, engineered articular 
Stress shielding
Protection of tissue from 
normal mechanical stresses by 
the presence of a much stiffer 
implant, often resulting in 
tissue loss.
Self-assembling process
A scaffold-free technology  
that produces tissues that 
demonstrate spontaneous 
organization without external 
forces via the minimization of 
free energy through cell-to-cell 
interactions.
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cartilage has achieved compressive and tensile moduli 
of ~0.32 MPa (rEF.100) and ~8 MPa (rEF.99), respectively, 
which are within the ranges of values for native articu-
lar cartilage (0.1–2 MPa and 5–25 MPa, respectively)101. 
Similarly, scaffold-free engineered menisci have com-
pressive and tensile moduli of ~0.12 MPa (rEF.102) 
and ~5 MPa (rEF.103), respectively, compared with the 
ranges of values for native tissue of 0.1–0.15 MPa and 
10–30 MPa, respectively88. Thus, scaffold-free meth-
ods have the potential to circumvent challenges asso-
ciated with scaffolds and to produce biomechanically 
functional implants.
Advances in scaffold-based and scaffold-free 
approaches have also focused on the recapitulation of 
native tissue architecture104–107. For example, stiffness 
gradient hydrogels (0.005–0.06 MPa) derived from 
poly(ethylene glycol) and chondroitin sulfate yield 
constructs with stiffness-dependent glycosamino-
glycan gradients that mimic the glycosaminoglycan 
gradient found in articular cartilage between the super-
ficial and deep zones104. In another study, bi-layered 
poly(ε-caprolactone) scaffolds with porous layers and 
aligned fibrous layers supported the development of 
zonal arrangement of engineered cartilage105. Collagen 
density and the alignment of porous collagen scaf-
folds can also be tailored via biaxial compression106, 
which might be useful for engineering anisotropy in the 
meniscus. Scaffold-free approaches have also been used 
to generate zonal tissue and anisotropy; for example, 
anisotropic menisci with zonal variations have been 
produced using the self-assembling process107. These 
studies104–107 suggest that recapitulating zonal and aniso-
tropic properties of cartilage and menisci might be 
necessary to impart native functional properties to a 
tissue-engineered product.
Engineering articular cartilage
Cell sources. Although chondrocytes are the obvious 
choice for use in engineering articular cartilage, the 
scarcity of chondrocytes necessitates cell expansion 
in vitro, which results in rapid dedifferentiation108. 
Although, to date, there is no evidence that dedifferen-
tiated cells can be redifferentiated in vivo, the results of 
some studies have suggested that redifferentiation can be 
Cell
expansion
Cell
redifferentiation
Tissue formation
Tissue
maturation
Tissue
implantation
Cell source
• Chondrocytes (knee, rib and nose)
• Fibrochondrocytes
• Tenocytes
• Fibrocytes
• Osteoarthritic chondrocytes
• MSCs or progenitor cells
Biochemical and biophysical  stimulation
• TGFβs
• BMPs
• IGFs
• FGFs
• c-ABC
• LOXL2
• Hyaluronic acid
• Matrilin 3
• Kartogenin
• Oxygen tension
Biomechanical stimulation
• Compression
• Tension
• Shear
• Hydrostatic pressure
• Biaxial loading
Agents used
in expansion
• TGFβs
• PDGFs
• FGFs
• EGFs
Agents used
in redifferentiation
• TGFβs
• BMPs
• GDFs
Scaffold-based or
scaffold-free approaches
Fig. 3 | advances in tissue engineering strategies for articular cartilage and meniscus. Engineered implants go through 
several stages of development that can be modified or enhanced by the addition of appropriate stimuli. The source of cells 
is important, as many cells dedifferentiate in culture. Alternative cell sources currently being trialled include non-articular 
chondrocytes, tenocytes, fibrocytes, osteoarthritic chondrocytes and stem cells or progenitor cells. Growth factors such as 
transforming growth factor βs (TGFβs), platelet-derived growth factors (PDGFs), fibroblast growth factors (FGFs), epidermal 
growth factor (EGF), bone morphogenetic proteins (BMPs) and growth and differentiation factors (GDFs) are used to 
effectively expand and help to redifferentiate cells before neotissue formation. Scaffold-based and scaffold-free methods 
can be used to engineer articular cartilage and menisci, and biochemical and biophysical factors such as TGFβs, BMPs, 
insulin-like growth factors (IGFs), FGFs, chondroitinase ABC (c-ABC), lysyl oxidase-like 2 (LOXL2), hyaluronic acid, matrilin 3, 
kartogenin and variations in oxygen tension are used to promote the maturation of engineered tissues. Similarly , 
biomechanical stimulation by , for example, compression, tension, shear, hydrostatic pressure and biaxial loading, can be 
used to improve the functional properties of the neotissue. MSC, mesenchymal stem cell.
Anisotropy
Having directionally dependent 
properties.
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accomplished in vitro109,110. For example, culturing either 
in vitro expanded chondrocytes or MSCs under 3D cul-
ture conditions supplemented with transforming growth 
factor-β1 (TGFβ1), growth and differentiation factor 5 
(GDF5) and bone morphogenetic protein 2 (BMP2), 
collectively termed aggregate redifferentiation, resulted 
in increased expression of the chondro genic genes 
SOX9, ACAN and COL2A1 compared with untreated 
cells111. Alternative cell sources include chondrocytes 
from non-articular cartilages; for example, costal (rib) 
chondrocyte-derived neocartilage has compressive 
properties on a par with those of native articular carti-
lage109. HOX-negative nasal chondrocytes are thought 
to possess greater self-renewal capacity than articular 
chondrocytes112 and a nasal chondrocyte-based arti-
cular cartilage product (N-TEC) is currently in clinical 
trials for articular cartilage repair in Europe113. In addi-
tion, constructs engineered using osteoarthritic chon-
drocytes have yielded neocartilage containing type II 
collagen and lubricin, but not type I collagen or type X 
collagen, which are indicative of chondrocyte dedif-
ferentiation and hypertrophy114. Thus, non-articular 
and osteoarthritic cartilage might yield viable cells for 
use in articular cartilage repair.
Adult MSCs derived from adipose tissue, bone 
marrow, synovium or skin have been extensively inves-
tigated for use in cartilage tissue engineering. Bone 
marrow-derived MSCs and umbilical cord blood-derived 
MSCs are already used to create engineered cartilage 
repair products, and dermis-derived MSCs and pre-
cursor cells have chondrogenic differentiation poten-
tial115,116. Other types of MSCs and progenitor cells are 
emerging as candidates for use in tissue engineering. For 
example, peripheral blood-derived MSCs and endothe-
lial progenitor cells have both been used to fill osteo-
chondral defects in rabbits117,118. In a non-controlled, 
clinical pilot study with 15 participants, adult CD146+ 
cartilage progenitor cells formed hyaline-like car-
tilage when implanted into knee articular cartilage 
defects119. After 12 months, the improvement in the 
international Knee Documentation Committee (iKDC) score 
was 52% and the improvement in the Lysholm score was 
71% compared with preoperative scores119. Notably, 
hypertrophy frequently occurs in MSCs during in vitro 
chondrogenic differentiation120, indicating the possi-
bility that MSC-derived neocartilage might progress 
towards endochondral ossification121, resulting in 
neotissue that is not suitable for cartilage repair and 
regeneration. Thus, despite promising early data, the 
long-term (>1 year) durability of MSC-derived tissues 
remains to be investigated.
Biochemical stimuli. Growth factors have long been 
recognized as important factors in neocartilage forma-
tion122, but other molecules are emerging as potential 
modulators of engineered cartilage. In the past few years, 
hyaluronic acid has been shown to stimulate chondro-
genesis and reduce hypertrophy in bone marrow-derived 
MSCs123 and in a co-culture of adipose-derived MSCs 
and chondrocytes124. Similar effects have also been 
shown for the addition of matrilin 3 to cultures of bone 
marrow-derived MSCs125. The addition of kartogenin 
induced chondrogenic differentiation in MSCs and 
reduced type II collagen breakdown by 1.8-fold in a 
mouse model of OA126; however, the therapeutic dose 
and long-term in vivo efficacy of kartogenin have yet 
to be determined, limiting its use127. Biophysical stimuli 
such as glycosaminoglycan-depleting enzymes (such as 
chondroitinase ABC) or crosslinking agents (such as lysyl 
oxidase-like 2 (LOXL2)) have also been used to increase 
collagen content and to form collagen crosslinks, lead-
ing to improved tensile properties in neocartilage128–130. 
In fact, a regimen of TGFβ1, chondroitinase ABC and 
LOXL2 applied after aggregate redifferentiation gen-
erated neocartilage with tensile modulus and ultimate 
tensile strength values approximately twice those of 
untreated neocartilage99. Oxygen tension also has an 
important role in chondrogenesis and in improving 
neotissue functional properties. In one study, hypoxia 
upregulated LOX expression in chondrocytes by 18-fold, 
leading to an increase in tensile stiffness of neocartilage 
by ~80% compared with neocartilage formed under 
normoxic conditions131. Overall, these studies suggest 
that novel biochemical and biophysical stimuli should 
be used for effective neocartilage formation.
Biomechanical stimuli. Biomechanical stimuli such as 
compression, shear and hydrostatic pressure are impor-
tant for cartilage homeostasis and are already used to 
improve the properties of engineered cartilage132. One 
advance in the use of biomechanical stimuli in tissue 
engineering has been the application of these stimuli to 
non-articular chondrocytes. Passive axial compression 
applied to costal chondrocytes increased the instanta-
neous modulus of engineered constructs by up to 92% 
compared with unstimulated neocartilage constructs133. 
Tension has also been trialled as an additional stimulus 
to improve the biomechanical properties of neocartilage. 
Tension stimulation of scaffold-free neocartilage treated 
with TGFβ1, chondroitinase ABC and LOXL2 resulted 
in increases of almost six-fold in tensile modulus and 
strength99. After in vivo implantation, these constructs 
had 90% of the collagen content and up to 94% of the 
tensile properties of native tissue99. A combination of 
compression and shear has also been tested, and resulted 
in a substantial increase in type II collagen production by 
chondrocytes in engineered neocartilage134. The results 
of these studies suggest that biomechanical stimulation 
has a pivotal role in engineering functional cartilage tis-
sue in vitro. Understanding biomechanical stresses in the 
native environment of the joint, as well as their effects 
on both the generation of robust neotissue in vitro and 
the generated tissue in vivo, is important for achieving 
clinical translation of engineered cartilage.
Engineering menisci
Cell sources. Although meniscal fibrochondrocytes 
might seem to be an obvious choice for engineering the 
meniscus, co-culturing these cells with others might be 
required to achieve the best results. Similar to chondro-
cytes, meniscal fibrochondrocytes dedifferentiate when 
expanded135, a fact that has led to the investigation of 
MSCs from the bone marrow136, synovium137 and adi-
pose tissue as alternative cell sources138. In a 2017 study, 
International Knee 
Documentation Committee 
(IKDC) score
A scoring system used to 
measure symptoms, sports and 
daily activities, current knee 
function and function before 
injury.
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COL1A1, COL2A1, ACAN and SOX9 were induced in 
tonsil-derived MSCs, and the feasibility of using these 
cells to repair meniscus defects was shown in rabbits139. 
Co-culture of synovium-derived stem cells and meniscus 
cells at a ratio of 1:3 increased glycosaminoglycan produc-
tion by ~82% compared with stem cell monoculture and 
by ~33% compared with meniscus cell mono culture140. 
These findings echo those of studies investigating the 
formation of neomenisci using co-cultures of chon-
drocytes and differentiated cells141 (such as tenocytes, 
ligament fibrocytes or meniscus fibrochondrocytes). 
For example, neomenisci formed using 50% articular 
chondrocytes and 50% meniscal fibrochondrocytes 
contain 700% more glycosaminoglycan and 90% more 
collagen than neomenisci formed using fibrochondro-
cytes alone97. The identification of new cell sources, 
as well as the optimization of co-culture systems, will 
both be important for overcoming the hurdles of cell 
culture for meniscus tissue engineering.
Biochemical stimuli. Growth factors including members 
of the TGFβ family, fibroblast growth factors (FGFs), 
platelet-derived growth factors (PDGFs) and epidermal 
growth factor (EGF) have shown efficacy in improving 
extracellular matrix production in engineered menis-
cus88. The addition of TGFβ1 and FGF2 stimulated 
collagen synthesis in meniscus constructs by 144% and 
60%, respectively, compared with untreated constructs, 
although only TGFβ1 was effective in stimulating glycos-
aminoglycan production142. Growth factors have also 
been used to induce lubrication in engineered menisci; 
the use of insulin-like growth factor 1 localized lubricin 
to the neotissue surface and resulted in a coefficient of 
friction of ~0.2 (rEF.143). Zonal development can also be 
engineered using growth factors. Modulating the release 
of TGFβ3 and connective tissue growth factor using 
3D-printed scaffolds resulted in MSC-derived menisci 
with zone-specific COL1A1 and COL2A1 expression, as 
well as zone-specific production of type I and type II 
collagen144. Other biochemical stimuli can also aid 
the production of engineered menisci with improved 
functional properties. Treatment of neofibrocartilage 
implants with a combination of TGFβ1, LOXL2 and 
chondroitinase ABC increased collagen crosslink forma-
tion by 3.8-fold compared with untreated implants103. 
Upon implantation, the tensile strength of the inter-
face of native meniscus and treated neofibrocartilage 
increased by 745% compared with the in vitro pro-
perties of untreated implants103. By contrast, changes in 
oxygen tension have yielded mixed results for engineer-
ing menisci. A 2017 study showed increased ACAN and 
COL2A1 expression, as well as proteoglycan and type II 
collagen production by expanded human meniscus 
fibrochondrocytes under hypoxic conditions145, whereas 
a 2013 study showed that normoxic conditions resulted 
in increased expression of COL2A1 and ACAN, as well 
as the production of type II collagen and aggrecan by 
expanded human fibrochondrocytes compared with 
hypoxic conditions146. Therefore, modulation of oxygen 
tension as a biochemical stimulus might hold promise 
for meniscus engineering130, but further investigations 
are needed to identify optimal culture conditions.
Biomechanical stimuli. The meniscus functions under 
compression, which results in the development of tensile 
hoop stress, therefore both of these mechanical forces are 
important for meniscus engineering. For example, using 
a compressive regimen of 10% strain at 1 Hz (which also 
results in tension), the collagen content, circumferential 
tensile modulus and radial tensile modulus of neomenis-
cus constructs can be increased compared with unstimu-
lated constucts147. Over the past few years, studies of the 
development of biomechanical stimuli for meniscus 
engineering have focused on replicating the native zonal 
arrangement and matrix-level organization. For example, 
application of sinusoidal hydrostatic pressure between 
0.55 and 5.03 MPa at 1 Hz for 4 h per day to aggregates 
of human fibrochondrocytes resulted in a substantial 
difference in type II collagen production between inner 
and outer zone meniscus fibrochondrocytes148, providing 
support for the use of this stimulus to help recapitulate 
zonal architecture. A bioreactor applying 5–10% com-
pressive strain was used to produce neomenisci with a 
fibrous collagen matrix in the outer zone that was similar 
in alignment to native tissue149. Investigations into how 
biomechanical stimuli can induce anisotropy in other 
engineered fibrocartilages have also been informative 
for meniscus engineering. For example, the application 
of passive axial compression during culture promoted 
anisotropic collagen organization similar to that seen in 
native tissue in tissue-engineered temporomandibular 
joint discs150. In addition to recapitulating native tissue 
biochemical and biomechanical properties, it is impor-
tant to mimic other native features such as anisotropy 
and zonal organization because these structural features 
are necessary for meniscus function.
Clinical studies
The technologies used to produce cell-based repair prod-
ucts for articular cartilage repair have been reviewed 
elsewhere151. This section focuses on the clinical appli-
cations of articular cartilage and meniscus repair prod-
ucts in development (TAbLE 1) and promising results 
from clinical trials of these products (TAbLE 2). Acellular, 
scaffold-based products are not discussed. Additional 
clinical studies that have been performed under 
Institutional Review Board approval and in accord-
ance with the principles of the Declaration of Helsinki, 
but not as part of registered clinical trials, are listed in 
Supplementary Table S1.
The majority of engineered cartilage products in 
the clinical pipeline, such as NOVOCART 3D and 
NeoCart, are manufactured using expanded autologous 
chondrocytes (TAbLE 1). Because chondrocytes dedif-
ferentiate upon in vitro expansion, products derived 
from expanded chondrocytes are likely to have infe-
rior biomechanical properties to those of native tissue. 
Strategies such as the application of hydrostatic pres-
sure have been developed to recover the chondrogenic 
pheno type. These strategies have resulted in articular 
cartilage repair implants that produce early-stage clinical 
improvements, but the long-term success and durability 
of these implants remains to be seen.
RevaFlex and CARTISTEM are both manufac-
tured using allogeneic cells (TAbLE 1). In a phase I/II 
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Table 1 | Cell-based tissue-engineered products for articular cartilage and meniscus repair
Product name 
(company)
Cell or tissue 
source
Seeding density Biomaterial or 
scaffold
Stimuli time between 
operations 
(time in culture)
No. of 
patient 
operations
Refs
Articular cartilage
BioCart II (ProChon 
Biotech)
Autologous 
chondrocytes 
(passage number 
unknown)
0.4 × 106 cells plus 
0.1 × 106 cells/cm2 
of scaffold
Freeze-dried 
fibrin–hyaluronan
Autologous 
serum and FGF2
3–4 weeks 
(3–4 days in 3D 
culture)
2 172,173
BioSeed-C (BioTissue 
SA)
Expanded 
autologous 
chondrocytes 
(passage number 
unknown)
20 × 106 cells per 
scaffold
Fibrin, polyglycolic 
acid, polylactic 
acid and 
polydioxanone
Autologous 
serum
4–5 weeks 2 174–176
BST-CarGel (Piramal 
Healthcare (Canada))
Autologous whole 
peripheral blood
3:1 ratio of 
autologous whole 
peripheral blood to 
biomaterial
Dissolved 
chitosan in 
glycerophosphate 
buffer
Unknown n/a 1 177
CaReS (Arthro 
Kinetics 
Biotechnology)
Primary autologous 
chondrocytes
Unknown Type I collagen 
hydrogel
Autologous 
serum
2 weeks (10–13 
days in 3D 
culture)
2 178
Cartilage autograft 
implantation system 
(CAIS) (DePuy Mitek)
Autologous 
cartilage fragments
1–2 mm minced 
cartilage dispersed 
onto scaffold
Absorbable 
co-polymer of 35% 
polycaprolactone 
and 65% 
polyglycolic 
acid with a 
polydioxanone 
mesh
Unknown n/a 1 179
Cartipatch (TBF 
Genie Tissulaire)
Expanded 
autologous 
chondrocytes 
(passage 3)
10 × 106 cells/ml of 
hydrogel
Agarose–alginate Autologous 
serum
6-7 weeks 2 180,181
CARTISTEM 
(Medipost)
Expanded, 
allogeneic, 
umbilical cord 
blood-derived 
MSCs (passage 
number unknown)
500 μl of hydrogel 
per cm2 of defect 
area, 5 × 106 cells/ml 
of hydrogel
Hyaluronic acid 
hydrogel
Fetal bovine 
serum
n/a 1 153
co.don 
Chondrosphere (co.
don AG)
Expanded, 
autologous 
chondrocytes 
(passage number 
unknown)
10–70 spheroids/cm2 
of defect area or 
~3 × 106 cells/cm2  
of defect area
Scaffold-free Autologous 
serum
~5–10 weeks 2 182,183
HYALOFAST (Anika 
Therapeutics)
Autologous BMAC 2 ml BMAC per 
scaffold
Benzyl ester of 
hyaluronic acid 
(HYAFF-11)
Unknown n/a 1 184
HYALOGRAFT C 
(Anika Therapeutics)
Expanded 
autologous 
chondrocytes 
(passage 1 or 
passage 2)
1.5–4 × 106 cells 
per scaffold
Benzyl ester of 
hyaluronic acid 
(HYAFF-11)
Autologous 
serum and 
TGFβ1
4 weeks (2 weeks 
in 3D culture)
2 185–188
INSTRUCT 
(CellCoTec B.V.)
Autologous, 
primary articular 
chondrocytes 
and bone 
marrow-derived 
cells
Unknown Poly((ethylene 
oxide) 
terephthalate-co- 
poly(butylene) 
terephthalate)
Unknown n/a 1 189
NOVOCART 3D 
(Aesculap Biologics)
Expanded 
autologous 
chondrocytes 
(passage 1)
0.5–3 × 106 cells/cm2  
of scaffold
Type I collagen and 
chondroitin sulfate
Autologous 
serum
3 weeks (2 days in 
3D culture)
2 190
NOVOCART Inject 
(TETEC AG)
Expanded 
autologous 
chondrocytes 
(passage number 
unknown)
Unknown In situ polymerized 
injectable 
albumin–
hyaluronic acid 
hydrogel
Autologous 
serum, BMP2 
and insulin
Unknown (3–4 
weeks in 2D 
culture)
2 157
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study, chondral defects treated with RevaFlex had 
grossly ‘normal or nearly normal’ cartilage repair (as 
measured by t he i nt er na tional Cartilage repair Society 
(iCrS)-Cartilage repair Assessment System) with no signs of 
immunological response after 1 year in 66.7% of patients 
treated152. In a study in South Korea, treatment of chon-
dral lesions with CARTISTEM improved clinical out-
comes compared with preoperative scores and there were 
no signs of bone or tumour growth up to 7 years after 
surgery153. CARTISTEM has completed a phase I/IIa 
study in the USA154. The successful clinical outcomes of 
allogeneic therapies to date open up a new avenue for 
eliminating donor site morbidity and the extra surgical 
step of tissue harvest when treating cartilage lesions.
Although engineered cartilage products in the clini-
cal pipeline are primarily indicated for knee defects, sev-
eral products have also been used in the hip (TAbLE 2). 
Treatment of acetabular chondral defects with BST- 
CarGel improved international Hip Outcome Tool (iHOT) 
scores by 46% in a retrospective case series of 37 
patients155. In a prospective study of 13 patients, treat-
ment of acetabular chondral delamination (average 
defect size 3.7 cm2) with BST-CarGel resulted in over 
90% filling by volume of each chondral defect after 
2 years156. In another study, the application of either 
NOVOCART 3D Inject or co.don Chondrosphere to 
acetabular cartilage defects (average size 2.21 cm2) pro-
duced substantial improvements in activity and quality 
of life and reduced pain after a mean of 19 months157.
Compared with articular cartilage, few clinical trials 
have been carried out with engineered meniscus products 
(TAbLE 2). For example, Cell Bandage, which is composed 
of autologous bone marrow-derived MSCs embedded in 
a collagen sponge, is placed between the torn edges of the 
meniscus and the defect is sutured closed. It is thought 
that the MSCs embedded in Cell Bandage release 
growth factors that promote defect repair158. In a first-in- 
human study, Cell Bandage improved IKDC scores 
by ~40 points, the Tegner–Lysholm score by ~40 points 
and the range of motion (rOM) score by ~10 degrees at 
12 months after surgery, and these results were main-
tained at 24 months158. In another study, Chondrogen 
injections containing 50 million or 150 million allo-
geneic bone marrow-derived MSCs also substantially 
decreased patient-reported visual analogue scale pain 
scores for up to 24 months159. Although meniscus repair 
products are not as numerous as articular cartilage 
products and fewer clinical trials have been performed, 
preliminary clinical data suggest positive outcomes for 
cell-based therapies.
Product name 
(company)
Cell or tissue 
source
Seeding density Biomaterial or 
scaffold
Stimuli time between 
operations 
(time in culture)
No. of 
patient 
operations
Refs
Articular cartilage (cont.)
NeoCart 
(Histogenics)
Expanded 
autologous 
chondrocytes 
(passage number 
unknown)
12 × 106 cells/ml 
collagen solution
Bovine type I 
collagen
Hypoxia and 
hydrostatic 
pressure
6–12 weeks 2 191–193
N-TEC (BIO-CHIP) Expanded 
autologous nasal 
chondrocytes 
(passage number 
unknown)
50 × 106 cells per 
membrane
Type I and type 
III collagen 
membrane 
(Chondro-Gide)
• Autologous 
serum, FGF2 
and TGFβ1 
(expansion)
• Autologous 
serum, 
insulin and 
ascorbic acid 
2-phosphate 
(3D culture)
≥7 weeks (2 
weeks in 2D 
culture and 2 
weeks in 3D 
culture)
2 194
RevaFlex (ISTO 
Technologies)
Expanded 
allogeneic juvenile 
chondrocytes 
(passage number 
unknown)
Unknown Scaffold-free Unknown n/a 1 152
Meniscus
Chondrogen 
(Mesoblast)
Expanded 
allogeneic 
adult bone 
marrow-derived 
MSCs (passage 2)
25 × 106 or 75 × 106 
cells/ml of sodium 
hyaluronate
Sodium 
hyaluronate
Fetal bovine 
serum 
(expansion)
n/a 1 159
Cell Bandage 
(Azellon)
Expanded 
autologous bone 
marrow-derived 
MSCs (passage 1)
1 × 106 cells/cm2 of 
scaffold
Collagen sponge 
from bovine 
corium
Fetal bovine 
serum and FGF 
(expansion)
>2 weeks (6 h in 
3D culture)
2 158
Acellular, scaffold-based products are not included. The term ‘chondrocytes’ refers to articular chondrocytes unless otherwise specified. The sponsors and 
products listed here might since have been acquired by other companies. BMAC, bone marrow aspirate concentrate; BMP2, bone morphogenic protein 2;  
FGF, fibroblast growth factor ; MSC, mesenchymal stem cell; n/a, not applicable; TGFβ1, transforming growth factor β1.
Table 1 (cont.) | Cell-based tissue-engineered products for articular cartilage and meniscus repair
International Cartilage 
Repair Society 
(ICRS)-Cartilage Repair 
Assessment System
A tool used to macroscopically 
evaluate the quality of cartilage 
repair tissue.
International Hip Outcome 
Tool
A tool used to measure 
symptoms, functional 
limitation, work-related 
concerns, sports and 
recreational activities, and 
social, emotional and lifestyle 
concerns using a visual 
analogue scale.
Tegner–Lysholm score
A patient-reported score of the 
effect of knee pain and stability 
on daily life.
Range of motion (ROM) 
score
A measurement of the range of 
flexion and extension of a joint.
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Table 2 | Clinical trials of cell-based tissue-engineered products for cartilage and meniscus repair
Product 
(company)
Clinical 
status
Study 
location
No. of 
patients
Clinical indication Comparator outcomes Refs
Articular cartilage
BioCart II 
(ProChon 
Biotech)
Phase II (status 
unknown)
USA and 
Israel
40 
(estimated)
Single, contained cartilage 
defect on the femoral 
condyle of the knee 
(1.5–7.5 cm2, depth up to 
6 mm)
Microfracture Results not published 195
BioSeed-C 
(BioTissue SA)
Phase III 
(ongoing)
Germany 80 Focal, contained, 
full-thickness cartilage 
defect on the lateral and 
medial condyles of the knee 
(Outerbridge grade III–IV)
chondrotissue 
(BioTissue SA)
Results not published 196
Non- 
interventional 
study 
(completed 
2016)
Germany 76 (target) Focal cartilage defects 
on the femoral condyles, 
trochlea and patella of 
the knee (>2 × 2 cm and 
Outerbridge grade III–IV) 
that have been previously 
treated with BioSeed-C
None Results not published 197
BST-CarGel 
(Piramal 
Healthcare 
(Canada))
Phase IV 
(terminated)
Canada 
and Europe
5 Single, focal, full-thickness 
cartilage defect on the 
femoral condyle of the knee 
(1.5–3 cm2 and ICRS grade 
III–IV)
Microfracture Results not published 198
Phase III (status 
unknown)
Unknown 50 
(estimated)
Focal chondral defects of 
the hip (>2 cm2)
Microfracture Results not published 199
RCT 
(completed 
2011)
Canada, 
South 
Korea and 
Spain
80 Focal cartilage defect on 
the medial femoral condyle 
of the knee (grade III–IV, 
unknown scoring system)
Microfracture • Improved lesion filling 
and quality of repair tissue 
superior to microfracture 
alone at 12 months
• Equivalent WOMAC scores 
and comparable safety 
outcomes between groups at 
12 months
177
Observational 
study 
(completed 
2014)
Canada 
and Spain
67 Focal cartilage defects on 
the femoral condyle of the 
knee (ICRS grade III–IV or 
Outerbridge grade III–IV)
Microfracture • Improved lesion filling 
and quality of repair tissue 
superior to microfracture 
alone at 5 years
• No difference in WOMAC 
scores and comparable safety 
outcomes between groups 
at 5 years
200
Cartilage 
autograft 
implantation 
system (CAIS) 
(DePuy Mitek)
Phase III 
(status 
unknown)
Singapore 36 
(estimated)
Full-thickness cartilage 
defect on the femoral 
condyle or trochlea of the 
knee (2–10 cm2)
Microfracture Results not published 201
Clinical trial 
(terminated)
USA and 
Canada
75 One or two focal chondral 
defects (1–10 cm2, 
depth up to 6 mm) or 
a non-osteochondritis 
dissecans lesion between 
grades I and III or an 
osteochondritis dissecans 
lesion between grades I 
and IV
Microfracture Results not published 202
CARTIPATCH 
(TBF Genie 
Tissulaire)
Phase III 
(terminated)
Belgium 40 Isolated femoral 
osteochondral defect 
(2.5–7.0 cm2, maximum 
depth of 10 mm, ICRS grade 
III–IV)
Microfracture Results not published 203
Phase III 
(completed 
2013)
Belgium 64 Single femoral 
osteochondral defect 
(2.5–7.0 cm2, maximum 
depth 10 mm, ICRS grade 
III–IV)
Microfracture Results not published 204
www.nature.com/nrrheum
R e v i e w s
Product 
(company)
Clinical 
status
Study 
location
No. of 
patients
Clinical indication Comparator outcomes Refs
Articular cartilage (cont.)
CARTIPATCH 
(TBF Genie 
Tissulaire)
Phase III 
(completed 
2013)
France 47 Isolated femoral 
osteochondral defect 
(2.5–7.5 cm2, ICRS grade 
III–IV)
Mosaicplasty • Decreased IKDC score 
compared with mosaicplasty 
at 24 months
• Decreased O’Driscoll score 
compared with mosaicplasty 
at 24 months
181
Phase II 
(completed 
2006)
France 17 Isolated chondral or 
osteochondral defect on 
the femoral condyles of the 
knee (1–5 cm2, ICRS grade 
III–IV)
None • Increased IKDC score at 
24 months compared with 
baseline
• 81% defect fill observed by 
MRI at 24 months
180
CARTISTEM 
(Medipost)
Phase I/II 
(completed 
2017)
USA 12 Single, focal, full-thickness 
cartilage defect of the knee 
(≥2 cm2, ICRS grade III–IV)
None Results not published 154
Phase III 
(completed 
2015)
South 
Korea
103 Cartilage defect of the knee 
(2–9 cm2, ICRS grade IV)
Microfracture Results not published 205
Phase III 
(completed 
2011)
South 
Korea
104 Cartilage defect of the knee 
(2–9 cm2, ICRS grade IV)
Microfracture Results not published 206
Phase I/II 
(completed, 
date 
unknown)
South 
Korea
7 Full-thickness cartilage 
defects of the knee (>2 cm2, 
Kellgren–Lawrence grade III 
and ICRS grade IV)
None • Maturing repair tissue by 
arthroscopy reported at  
12 weeks
• Improved VAS pain score  
and IKDC score at  
24 months compared with 
pre-transplantation scores
• Regenerated cartilage 
detected by MRI at 36 months
• Improved outcomes stable 
and no signs of osteogenesis 
or tumorigenesis at 7 years
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co.don 
Chondrosphere 
(co.don AG)
Phase III 
(active, not 
recruiting)
Germany 
and Poland
102 Isolated single chondral 
defect on the femoral 
condyle of the knee 
(1–4 cm2, depth up to 6 mm, 
ICRS grade III–IV)
Microfracture Results not published 207
Phase II 
(completed 
2018)
Germany 75 Isolated single chondral 
defect or osteochondritis 
dissecans lesion on the 
femoral condyle, trochlea, 
tibia or retropatella 
(4–10 cm2, depth up to 
6 mm, ICRS grade III–IV)
Different doses 
of co.don 
Chondrosphere
No substantial differences 
in the incidence of adverse 
events reported between the 
different doses
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HYALOFAST 
(Anika 
Therapeutics)
Prospective 
study 
(recruiting)
USA and 
Europe
200 
(estimated)
Cartilage defect on the 
femoral condyle or trochlea 
(1–6 cm2, ICRS grade III–IV)
Microfracture Results not published 209
INSTRUCT 
(CellCoTec 
B.V.)
Prospective 
study 
(completed 
2014)
Europe 40 Cartilage defect on the 
femoral condyle and 
trochlea of the knee 
(modified Outerbridge 
grade III–IV)
None • Graft delamination reported 
in two patients leading to 
treatment failure in one patient
• ~90–100% defect filling at  
24 months
• Improved VAS pain score 
and IKDC score at 24 months 
compared with baseline
• Improved KOOS at 12 months 
compared with baseline
• Histological presence of 
hyaline cartilage in 72% 
of tissue samples and 
fibrocartilage and hyaline 
cartilage in 97% of tissue 
samples
• Presence of repair tissue 
detected by MRI at 12 months
189
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Product 
(company)
Clinical 
status
Study 
location
No. of 
patients
Clinical indication Comparator outcomes Refs
Articular cartilage (cont.)
NOVOCART 
3D and 
NOVOCART 
3D Plus 
(Aesculap 
Biologics, 
TETEC AG)
Phase III 
(recruiting); 
NOVOCART 
3D
USA 30 
(estimated)
Patients in whom 
microfracture failed in a 
previous trial
None Results not published 210
Observational 
study (active, 
not recruiting); 
NOVOCART 
3D
Germany 81 Localized, full-thickness 
cartilage defect of the knee 
(2.5–10 cm2, ICRS grade 
III–IV)
None Results not published 211
Phase III 
(recruiting); 
NOVOCART 
3D
USA and 
Canada
233 
(estimated)
Isolated cartilage defects on 
the femoral condyle of the 
knee (2–6 cm2)
Microfracture Results not published 212
Phase III 
(active, not 
recruiting); 
NOVOCART 
3D Plus
Europe 263 One or two cartilage 
defects on the femoral 
condyle and/or the trochlea 
of the knee (2–6 cm2, ICRS 
grade III–IV)
Microfracture Results not published 213
NOVOCART 
Inject and 
NOVOCART 
Inject Plus 
(TETEC AG)
Phase III 
(recruiting); 
NOVOCART 
Inject Plus
Europe 100 One or two focal cartilage 
defects on the femoral 
condyle, trochlea, patella 
or tibial plateau of the knee 
(4–12 cm2, ICRS grade III–IV)
None Results not published 214
Non- 
interventional 
study 
(recruiting); 
NOVOCART 
Inject
Germany 245 
(estimated)
‘Insulated’ full-thickness 
cartilage defects of the knee 
(2.5–10 cm2, ICRS grade 
III–IV)
None Results not published 215
Observational 
study 
(active, not 
recruiting); 
NOVOCART 
Inject
Germany 21 ‘Insulated’ full-thickness 
cartilage defects of the hip 
(1.5–10 cm2, ICRS grade III)
None Results not published 216
NeoCart 
(Histogenics)
Phase III 
(active, not 
recruiting)
USA 245 Cartilage defect of femur 
and/or trochlea of the knee
Microfracture Results not published 217
Phase II 
(completed 
2014)
USA 30 Cartilage defect on the 
femoral condyle of the knee 
(ICRS grade III)
Microfracture • No difference in adverse 
event rates between groups
• Greater improvement in 
KOOS, IKDC and VAS pain 
scores at 6, 12 and 24 months 
compared with microfracture
• Improved MOCART scores 
at 24 months compared with 
scores at 3 months
• Improved KOOS, SF-36 
and IKDC scores at 5 years 
compared with baseline
• Decreased VAS pain score and 
improved range of motion at 5 
years compared with baseline
191,218
Phase I 
(completed, 
date 
unknown)
USA 8 Full-thickness cartilage 
defect on the femoral 
condyle of the knee (grade 
III, unknown scoring system)
None • Improved VAS pain score at 
12 months compared with 
baseline
• Improved IKDC score and 
range of motion at 24 months 
compared with baseline
• Six patients with 67–100% 
defect filling, one patient with 
33–66% defect filling and one 
patient with <33% defect 
filling as determined by MRI
• No arthrofibrosis or implant 
hypertrophy found
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Challenges to clinical translation
Cell sourcing
Obtaining sufficient numbers of autologous cells remains 
a major limiting factor to the translation of engineered 
articular cartilage and meniscus products (Fig. 4a). As 
previously noted, sourcing cells from non-articular 
cartilages, such as costal cartilage, might be a solution 
to the lack of autologous chondrocytes, although passag-
ing might still be necessary with these cells. Expression 
of COL1A1 and COL2A1 by these cells decreases after 
just one passage108, but although this collagen expres-
sion profile is undesirable for engineering articular 
Product 
(company)
Clinical 
status
Study 
location
No. of 
patients
Clinical indication Comparator outcomes Refs
Articular cartilage (cont.)
N-TEC 
(BIO-CHIP)
Phase II 
(recruiting)
Europe 108 
(estimated)
One or two localized 
cartilage defects on the 
femoral condyle and/or  
trochlea of the knee 
(2–8 cm2, ICRS grade III–IV)
N-CAM 
(BIO-CHIP)
Results not published 113
Phase I 
(completed 
2018)
Switzerland 10 One or two cartilage 
defects on the femoral 
condyle and/or trochlea 
of the knee (2–8 cm2, ICRS 
grade III–IV)
None • No adverse events
• Defect filling with repair 
tissue variable
• Improved KOOS and 
IKDC scores at 24 months 
compared with pre-operative 
values
• Approaching ‘ideal level’ of 
glycosaminoglycan content 
determined by ΔR1 (R1 = 1/T1) 
and water and collagen 
contents ‘similar to those in 
native tissue’ at 24 months
194
RevaFlex (ISTO 
Technologies)
Phase III 
(terminated)
USA 14 One or two cartilage 
defects on the femur of the 
knee (≤5 cm2)
Microfracture Results not published 219
Phase I/II 
(completed, 
date 
unknown)
USA 9 Up to two cartilage defects 
on the femoral condyle 
or trochlea of the knee 
(1–5 cm2, ICRS grade III–IV)
None • Improved patient-reported 
outcome measures at  
12 months
• Cartilage repair graded as 
grossly normal/near normal 
in 66.7% of patients at  
12 months
• Maturation of the implant 
(determined by defect filling 
and quality of repair tissue) 
observed by MRI at  
12 months
152
Meniscus
Chondrogen 
(Mesoblast)
Phase I/II 
(completed 
2011)
USA 55 Following meniscectomy Placebo 
(hyaluronan)
Results not published 220
Phase I/II 
(completed 
2008)
USA 55 Following meniscectomy Placebo 
(hyaluronan)
• Three patients with >15% 
increase in meniscus volume 
in group receiving 50 × 106 
cells, 0 in the control group 
and 0 in group receiving 
150 × 106 cells at 24 months
• Decreased VAS pain score 
and increased Lysholm score 
in all treatment groups at 
24 months compared with 
baseline
159
Cell Bandage 
(Azellon)
Phase I 
(ongoing)
Europe 10 Meniscus tear that would 
otherwise be treated by 
meniscectomy (white–white 
zone)
None Results not published 221
Acellular scaffold-based products are not included. The term ‘Europe’ refers to trials that took place in three or more European countries; if a trial took place in 
fewer than three European countries, all countries are listed. The sponsors and products listed here might since have been acquired by other companies. ICRS, 
International Cartilage Repair Society ; IKDC, International Knee Documentation Committee; KOOS, Knee Injury and Osteoarthritis Outcome Score; MOCART, 
magnetic resonance observation of cartilage repair tissue; R1, longitudinal relaxation rate; RCT, randomized controlled trial; SF-36, short form-36; T1, longitudinal 
relaxation time; VAS, visual analogue scale; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.
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cartilage, passaged cells that express COL1A1 might still 
be useful in meniscus tissue engineering because native 
meniscus contains ~80% type I collagen in the red–red 
zone88. Furthermore, a spectrum of engineered cartilages 
from hyaline to fibrous can be engineered from costal 
chondro cytes by modulating their redifferentiation after 
passaging160. Innovative use of cells and non-articular 
cartilage cell sources has the potential to greatly alleviate 
the scarcity of cells for autologous articular cartilage and 
meniscus therapies.
Biological variability
Biological variability between donors makes the con-
sistent production of high-quality autologous neotis-
sue difficult to achieve (Fig. 4a). Not all donors possess 
cells capable of forming robust neotissue. For example, 
chondrocytes sourced from 64–80-year-old donors 
exhibited variable expression of chondrogenic genes 
at passage two161. In cells from one group of donors, 
COL2A1 expression increased when the cells were 
cultured as a microtissue compared with monolayer 
culture, whereas in cells from another group of donors, 
COL2A1 expression did not increase upon microtissue 
culture161. Using allogeneic cells would reduce problems 
related to donor variability during manufacturing, but 
the allogeneic implants would need to be well tolerated 
by the recipient. Several cartilage repair products already 
include allogeneic cells or tissues (TAbLE 1). Lending fur-
ther credence to this approach, healing of temporoman-
dibular joint disc defects using allogeneic neocartilage 
has been achieved in mini-pigs162. In that study, costal 
chondrocyte-generated neocartilage implants were well 
Bench Bedside
a  Technical challenges and solutions to translation
b  Regulatory solutions to implementation
Cell sourcing for autologous therapies
Non-articular cartilage sources
Knee Hip
Biological variability affecting consistent tissue quality
Allogeneic sources, donor screening
Implant protection, tissue integration
Tissue priming
Novel surgical
approaches
Modiﬁcation against
immune-mediated
degeneration
Knee Hip
Donor knee
Arthritic knee
LOXL2 c-ABC
Rib Donor rib
Donor
screening
RMAT
designation
Accelerated
programmes
Surrogate
end points
Fig. 4 | Challenges to the clinical translation of engineered cartilage and meniscus products. a | The main technical 
challenges to clinical translation include obtaining sufficient numbers of autologous cells, the effects of biological 
variability on the consistent production of high-quality engineered tissues and integration of the engineered tissues once 
implanted in vivo. Potential solutions and avenues of further investigation include: cells sourced from non-articulating 
cartilage (such as costal (rib) cartilage); allogeneic approaches, including extensive screening to identify appropriate 
donors; modification of engineered tissues to withstand immune-mediated degeneration within an inflamed joint; 
priming of engineered tissues with chondroitinase ABC (c-ABC) and lysyl oxidase-like 2 (LOXL2) for enhanced integration; 
and novel in vivo implantation methods that protect tissue-engineered implants. b | Regulatory challenges to clinical 
translation include the long time-frames and high costs associated with clinical trials. It is hoped that solutions such as the 
Regenerative Medicine Advanced Therapy (RMAT) designation, other FDA programmes that enable accelerated review 
and approval of applications, and the use of surrogate end points will help overcome these challenges.
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tolerated immunologically and resulted in a decrease in 
OA162. Although there is increased concern about dis-
ease transmission with the use of allogeneic approaches, 
tissue banks already provide allogeneic cells and tissues 
for transplantation in accordance with FDA guidance 
on donor screening and testing163. Thus, the use of 
well-characterized allogeneic cells might avoid disease 
transmission while mitigating the intractable problem 
of biological variability.
Achieving biomimicry
Insofar as the functions of articular cartilage and the 
meniscus are to distribute loads and enable frictionless 
joint movement, tissue engineering efforts should reflect 
these functions. Advances have been made in improv-
ing the robustness of engineered cartilage towards native 
tissue values; however, considerable efforts are still 
required to engineer tribological properties and durability 
into neocartilage and neomenisci to achieve biomimicry. 
It has been well documented that a functionality index 
(FI) enables comparison of the quality of engineered tis-
sues relative to healthy native tissues100,109,150. However, to 
be more powerful, the FI should be modified to reflect 
the relevant salient properties of each target tissue, such 
as including the coefficient of friction for articular carti-
lage or an anisotropy index for the meniscus. Although 
complete biomimicry (FI = 1) in engineered cartilage 
has traditionally been the goal of tissue engineering 
approaches, a 2018 study162 in which the implantation 
of engineered cartilage with an FI of 0.42 resulted in 
the complete healing of temporomandibular joint disc 
defects raises the question as to the degree of biomimicry 
necessary to achieve regeneration. It remains to be seen 
whether the achievement of biomimicry, especially with 
respect to biomechanical properties, imparts long-term 
durability to neotissue in vivo. Furthermore, no data 
exist to definitively show that the repair of articu-
lar cartilage and meniscus damage delays or halts the 
progression of OA. The ability of small defect repairs 
to stop OA progression would be difficult to assess in 
a well-controlled, randomized clinical trial owing to 
the need to include a no-treatment study arm and the 
long time-frames involved. Although evidence exists 
that neotissue with an FI of <1 elicits successful heal-
ing and that complete biomimicry might not be neces-
sary162, data on the long-term outcomes of using such 
an approach are lacking. Thus, it will be instructive to 
continue examining the degree of biomimicry necessary 
to ensure satisfactory long-term healing outcomes.
Implant integration and protection
The clinical translation of tissue-engineered products 
requires many factors to be taken into consideration 
beyond the manufacture of robust neotissue. Articular 
cartilage and the white–white zone of the meniscus are 
avascular, which makes integration of implants into 
existing native tissue difficult (Fig. 4a). The removal of 
anti-adhesive glycosaminoglycans and the priming 
of engineered tissue with collagen crosslinking agents 
are promising strategies that have shown preliminary 
success towards improving implant integration. For 
example, chondroitinase ABC treatment of native 
articular cartilage plugs before they are press-fitted into 
an articular cartilage annulus resulted in an integrated 
assembly with interfacial shear strength of 0.135 MPa, 
compared with 0.068 MPa in the untreated control164. In 
another study, LOXL2 treatment of similar assemblies of 
engineered cartilage and native cartilage rings resulted 
in a 2.2-fold increase in interfacial stiffness165. Implant 
integration can also be affected by post operative 
recovery regimens. Unlike humans, animals operated 
on in preclinical studies will not obey strict rehabilita-
tion regimens and might disrupt implant integration 
by engaging in impulsive physical activity immediately 
after surgery. Thus, in both animals and humans, the 
use of novel tissue-engineered implants might require 
novel surgical procedures that protect engineered 
implants and prevent implant displacement. For exam-
ple, a reproducible intralaminar fenestration technique 
has been developed that enables engineered neocarti-
lage to be secured into native tissue without directly 
suturing the implant162. Because implant integration, 
surgical techniques and rehabilitation all contribute 
to the efficacy of cartilage regeneration, developing 
appropriate protocols to address these factors should 
be as much of a priority for researchers as developing 
the implants themselves.
Inflammation and immunogenicity
Upon implantation, engineered neotissue must also 
withstand the pro-inflammatory environment of the 
injured or diseased joint. Chronic joint inflammation 
(as can be present in OA and RA) can be destructive 
to tissue-engineered implants and impede their inte-
gration and performance. Many studies have examined 
ways to ameliorate the immune response to ensure the 
survival of tissue-engineered implants in inflammatory 
environments, such as joints affected by OA and RA. 
Macrophage phenotypes can be modulated in vitro to 
promote healing and to potentially reduce inflammation 
in OA166. Other strategies to reduce inflammation, such 
as the use of adipose-derived MSCs to reduce matrix 
metalloproteinase 3 (MMP3) and MMP13 expression, 
also hold promise167. The rejection of allogeneic engi-
neered cartilage and menisci is also a concern. Although 
articular cartilage is considered to be immune privileged, 
and fresh allografts (such as osteochondral allografts, 
DeNovo NT and meniscus allografts) are in current 
clinical use, the degree of immune privilege an implant 
has depends on its location within the knee joint and 
its proximity to the synovium28. Meniscus allografts are 
well tolerated, but it remains to be seen whether allo-
geneic neomenisci implanted into the vascular red–red 
zone of the meniscus would elicit an immune response. 
Osteochondral allografts are frequently used in articular 
cartilage repair and are well tolerated33 despite the fact 
that the subchondral bone is vascularized, lending some 
support to the idea that red–red zone allografts might be 
tolerated. However, most irreparable meniscus defects 
that would require engineered meniscus grafts occur in 
the white–white zone, which does not contain vascu-
lature. Thus, this area might also possess a degree of 
immune privilege, similar to articular cartilage, although 
the exact immune privilege status of the meniscus still 
Tribological properties
Functional properties relating 
to friction and lubrication  
of tissues.
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needs further study. Efforts to minimize the immuno-
genicity of allogeneic and xenogeneic articular carti-
lage and menisci include decellularization and antigen 
removal168–170, but these methods typically create a dis-
rupted matrix and non-viable cells, depriving the neo-
tissue of the capacity for homeostasis, remodelling and 
integration. A variety of immunological challenges asso-
ciated with cartilage and meniscus tissue engineering, 
such as the pro-inflammatory environment of arthritic 
joints and the antigenicity of allogeneic cells and matrix 
components, indicate that neotissue should be modi-
fied to be able to withstand or modulate the immune 
response to ensure graft survival and integration.
Regulatory concerns
Several regulatory hurdles surround the translation of 
engineered cartilage and meniscus products into patients 
(Fig. 4b). Clinical trials to examine the safety and efficacy 
of engineered cartilage and meniscus products in large 
patient populations are costly and time-consuming. 
Recognizing this, the FDA has announced a new policy 
framework to expedite the approval of new therapies 
while preserving public health via a risk-based approach. 
Special designations, such as the Regenerative Medicine 
Advanced Therapy (RMAT) designation, have been cre-
ated to expedite the approval process171. Advantages of 
the RMAT designation include FDA assistance as early 
as the phase I trial stage, the discussion of potential sur-
rogate or intermediate end points to accelerate approval 
and eligibility for priority review of marketing applica-
tions. The use of surrogate end points might accelerate 
time to market by shifting some of the burden of proof to 
post-market follow-up studies. The RMAT designation, 
as well as other special designations and accelerated pro-
grammes171, might be solutions to reducing the cost and 
time required to gain marketing approval for engineered 
articular cartilage and meniscus products.
Conclusions
Current surgical repair techniques for articular cartilage 
and meniscus pathologies are insufficient to halt the devel-
opment and progression of OA, which has accelerated the 
development of alternative tissue engineering strategies. 
Many advances have been made in cell sourcing and the 
use of stimuli to engineer neotissue akin to native articu-
lar cartilage and menisci, which can potentially provide 
long-term solutions for cartilage and meniscus healing. For 
example, the use of cells from allogeneic, non-articulating 
and/or diseased cartilage might counter the lack of native 
autologous cells. Although the goal of tissue engineering 
is to achieve biomimicry, tissue engineering approaches 
must also aim to create neotissue that withstands joint 
inflammation, readily integrates into surrounding native 
tissues and ensures positive outcomes regardless of biolog-
ical variability and the age of the patient. The progression 
towards the use of cell-based tissue-engineered therapies 
in the clinic can be seen in the numerous clinical trials 
and Institutional Review Board-approved studies that are 
currently underway. Although most products are primar-
ily indicated for use in the knee, many of the same engi-
neering principles can be translated to the development 
of products for other joints such as the hip. The estab-
lishment of the RMAT designation should accelerate the 
regulatory process for these products. Rapidly emerging 
tissue engineering technologies could lead to the develop-
ment of long-lasting products that are readily available off 
the shelf for articular cartilage and meniscus regeneration 
in the not-so-distant future.
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